Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID 19 hospitalized meta-analysis

Ader (lopinavir/ritonavir)
  NCT04315948		 RCTlopinavir/ritonavirCOVID 19 hospitalizedsome concern
-/- ongoing
    Nojomi
          IRCT20180725040596N2    		 RCTlopinavir/ritonavirumifenovir (arbidol)COVID 19 hospitalizedsome concern
    		50/50 inconclusive
      RECOVERY
              NCT04381936      		 RCTlopinavir/ritonavirstandard of careCOVID 19 hospitalizedsome concern
      		1616/3424 inconclusive
      • inconclusive 3 % increase in deaths (PE) with a moderate degree of certainty due to some concern in risk of bias
      the trial Steering Committee concluded that there is no beneficial effect of lopinavir-ritonavir in patients hospitalised with COVID-19 and closed randomisation to that treatment arm
      SOLIDARITY (lopi/rito)
              NCT04315948      		 RCTlopinavir/ritonavirstandard of careCOVID 19 hospitalizedsome concern
      		1399/1372 inconclusive
      • inconclusive 0 % increase in deaths (PE) with a moderate degree of certainty due to some concern in risk of bias
      Chen_lopi_rito OBSlopinavir/ritonavirstandard of careCOVID 19 hospitalizedcritical
      		60/121 inconclusive

        COVID-19 mild to moderate meta-analysis

        ELACOI (lopinavir/ritonavir)
                  NCT04252885        		 RCTlopinavir/ritonavirstandard of careCOVID-19 mild to moderatesome concern
        		21/7 inconclusive

          COVID-19 severe or critically meta-analysis

          Cao
                      ChiCTR2000029308          		 RCTlopinavir/ritonavirstandard of careCOVID-19 severe or criticallysome concern
          		99/100 suggested
          • inconclusive 31 % increase in clinical improvement,clinical improvement (time to event analysis only) (PE) with a moderate degree of certainty due to some concern in risk of bias
          • suggested 94 % increase in clinical improvement (14-day) with a moderate degree of certainty due to some concern in risk of bias
          REMAP-CAP (lopinavir/ritonavir only)
                      NCT02735707          		 RCTlopinavir/ritonavirstandard of careCOVID-19 severe or criticallysome concern
          		268/377 safety concern
          • statistically significant 17 % decrease in hospital discharge with a moderate degree of certainty due to some concern in risk of bias

          PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
          Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

           

          - About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons